Skip to content
DraconiticResearch
Search Sources API
182,549 studies31 sourcesUpdated 30 min ago
PreprintCC BY-NCbioRxiv

MMRi62 induces iron depletion-driven apoptosis through a ferritin-independent mechanism

  1. 1Centre Scientifique de Monaco

Abstract

The modulation of iron metabolism is increasingly explored as a therapeutic strategy in cancer, particularly through the induction of ferroptosis. Given the central role of ferritin as a major intracellular iron buffer, targeting ferritin represents an attractive strategy to disrupt iron homeostasis; however, the lack of pharmacological approaches capable of selectively targeting ferritin currently limits the therapeutic exploitation of this vulnerability. MMRi62, initially developed to target the MDM2-MDM4 axis, has been proposed to induce ferroptosis via ferritin degradation. Here, we revisited this hypothesis in the context of medulloblastoma (MB). Contrary to this proposed mechanism, we found that MMRi62 does not trigger ferroptosis but instead induces robust apoptotic cell death. This effect is observed in both p53-mutant DAOY and p53 wild-type HD-MB03 cells, as well as in c-Myc/OTX2-driven medulloblastoma-like tumours genetically induced in brain organoids. Although ferritin degradation occurs upon treatment, genetic dissection demonstrates that neither ferritin itself nor ferritinophagy are required for MMRi62-induced cytotoxicity. Together, these findings rule out ferritin-dependent mechanisms as primary drivers of cytotoxicity. Instead, we uncovered that MMi62 induces a profound rewiring of iron metabolism consistent with a canonical iron starvation response, accompanied by a marked reduction in intracellular iron levels. Consistently, the UV-visible spectroscopic data were in agreement with the proposed iron-chelating properties of MMRi62. Taken together, our findings identify iron depletion-driven apoptosis, rather than ferroptosis, independently of ferritin degradation, as the primary mechanism of MMRi62 cytotoxicity in MB, refining its mode of action and highlighting iron homeostasis as a therapeutic vulnerability.

Related

  1. A nitric oxide donating β-elemene derivative induces reactive oxygen species associated apoptosis and reduces STAT3 phosphorylation in medulloblastoma cells
    Jun Rong, Jianqiang Guo, Qiang Zhou +5
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  2. Fisetin Induces Apoptosis and Inhibits Migration of Melanoma Cells by Suppressing Glycolytic Metabolism via PKM2 Inhibition.
    Yoon-Jin Lee, Ki Dam Kim, Min Hyuk Choi +7
    Annals of dermatologyPeer-reviewedCC BY-NCFull textPharmacology & toxicologyEurope PMC
  3. Honokiol induces an autophagy and apoptosis imbalance by modulating the p62 and Nrf2 signaling loop in canine osteosarcoma
    Juhyeong Seo, Minha Jeong, Jiyeon Ham
    Scientific ReportsPeer-reviewedCC BYFull textGeneral medicineDOAJ
  4. Miltirone suppresses proliferation and induces apoptosis in ovarian cancer cells in association with modulation of the RBM15/E2F2/PI3K/Akt signaling axis
    Yuesong Wang, Yongju Tian, Dake Zhang +1
    Scientific ReportsPeer-reviewedCC BYFull textObstetrics, gynaecology & paediatricsDOAJ
  5. Combined celecoxib and NDGA induces a non-canonical, autophagy-independent redox cell death via p62/KEAP1 in colorectal cancer
    R. Yadala, S. palakurthi, S. Pawar
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
BibTeX
@misc{segui2026mmri62,
  title = {{MMRi62 induces iron depletion-driven apoptosis through a ferritin-independent mechanism}},
  author = {F. Segui and M. Pagnuzzi and J. Antiq and J. Durivault and V. Vial and N. Bogliotti and I. Leray and M. Vucetic and V. Picco},
  howpublished = {bioRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.22.753515},
  url = {https://www.biorxiv.org/content/10.64898/2026.09.22.753515v1},
  note = {CC BY-NC},
}
RIS
TY  - UNPB
TI  - MMRi62 induces iron depletion-driven apoptosis through a ferritin-independent mechanism
AU  - F. Segui
AU  - M. Pagnuzzi
AU  - J. Antiq
AU  - J. Durivault
AU  - V. Vial
AU  - N. Bogliotti
AU  - I. Leray
AU  - M. Vucetic
AU  - V. Picco
PY  - 2026
DA  - 2026/09/22
PB  - bioRxiv
DO  - 10.64898/2026.09.22.753515
UR  - https://www.biorxiv.org/content/10.64898/2026.09.22.753515v1
AB  - The modulation of iron metabolism is increasingly explored as a therapeutic strategy in cancer, particularly through the induction of ferroptosis. Given the central role of ferritin as a major intracellular iron buffer, targeting ferritin represents an attractive strategy to disrupt iron homeostasis; however, the lack of pharmacological approaches capable of selectively targeting ferritin currently limits the therapeutic exploitation of this vulnerability. MMRi62, initially developed to target the MDM2-MDM4 axis, has been proposed to induce ferroptosis via ferritin degradation. Here, we revisited this hypothesis in the context of medulloblastoma (MB). Contrary to this proposed mechanism, we found that MMRi62 does not trigger ferroptosis but instead induces robust apoptotic cell death. This effect is observed in both p53-mutant DAOY and p53 wild-type HD-MB03 cells, as well as in c-Myc/OTX2-driven medulloblastoma-like tumours genetically induced in brain organoids. Although ferritin degradation occurs upon treatment, genetic dissection demonstrates that neither ferritin itself nor ferritinophagy are required for MMRi62-induced cytotoxicity. Together, these findings rule out ferritin-dependent mechanisms as primary drivers of cytotoxicity. Instead, we uncovered that MMi62 induces a profound rewiring of iron metabolism consistent with a canonical iron starvation response, accompanied by a marked reduction in intracellular iron levels. Consistently, the UV-visible spectroscopic data were in agreement with the proposed iron-chelating properties of MMRi62. Taken together, our findings identify iron depletion-driven apoptosis, rather than ferroptosis, independently of ferritin degradation, as the primary mechanism of MMRi62 cytotoxicity in MB, refining its mode of action and highlighting iron homeostasis as a therapeutic vulnerability.
ER  -